Although interleukin (IL)-9 has been extensively studied in inflammation and autoimmune diseases, the expression level of IL9 in colon cancer and its clinical significance are less well established. In total, 15 healthy donors (HDs) and 60 patients who had been diagnosed with
colon cancer that had undergone a surgical resection were enrolled in the study. The plasma levels of IL9 in the HDs and cancer patients were detected by the liquid chip technique, while the expression levels of IL9 in the colon cancer tissues and normal tissues were analyzed using immunohistochemistry
(IHC) and reverse transcriptionquantitative polymerase chain reaction (RTqPCR). Finally, the difference in the expression levels of IL9 between the patients classified as tumornodemetastasis stage and stage was compared. The results demonstrated that the plasma levels of IL9 in
the patients with colon cancer were significantly lower when compared with the HDs (1.29 vs. 2.53 pg/ml, P<0.05). Furthermore, according to the IHC and RTqPCR results, low expression levels of IL9 were observed in the colon cancer tissues when compared with the normal tissues (P<0.05).
With regard to the plasma and tumor tissue samples, patients diagnosed with stage colon cancer expressed lower levels of IL9 compared with the stage patients (P<0.05). In conclusion, low expression levels of IL9 were observed in the tissue and plasma samples collected from the
colon cancer patients, and the decreased expression of IL-9 was shown to correlate with colon cancer progression.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Gastroenterological Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China
Department of Colorectal and Anal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Publication date: January 1, 2015
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites